SCHEMBL15913286

SCHEMBL15913286

COC(=O)c1ccc2oc(CCl)nc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.50
MAPT P10636 7/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
TP53 P04637 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
NPC1 O15118 5/20 0.49
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
S1PR1 P21453 1/20 0.44
S1PR3 Q99500 1/20 0.44
ALOX5AP P20292 1/20 0.44
FEN1 P39748 1/20 0.44
MEN1 O00255 1/20 0.43
STAT3 P40763 1/20 0.43
KMT2A Q03164 1/20 0.43
HSPD1 P10809 1/20 0.43
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31737855 0.89 MAPT (0.51) RAB9AMAPTSMN1; SMN2TP53NPC1
SCHEMBL17221764 0.87 GAA (0.57) RAB9AMAPTSMN1; SMN2TP53NPSR1
SCHEMBL9374745 0.86 SLC27A1 (0.49) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL9179783 0.86 RAB9A (0.50) RAB9AMAPTSMN1; SMN2TP53NPSR1
SCHEMBL11339141 0.83 RAB9A (0.47) RAB9AMAPTSMN1; SMN2TP53NPSR1
SCHEMBL4155905 0.82 MBOAT4 (0.49) RAB9ASMN1; SMN2NPC1KDM4EHPGD
SCHEMBL3118574 0.82 MAPT (0.61) RAB9AMAPTTP53NPC1
SCHEMBL29364254 0.81 MAPT (0.53) RAB9AMAPTSMN1; SMN2TP53NPSR1
SCHEMBL1096761 0.81 MAPT (0.53) RAB9AMAPTSMN1; SMN2TP53NPSR1
SCHEMBL15823611 0.81 RAB9A (0.47) RAB9AMAPTSMN1; SMN2TP53NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3402799-B1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARM INC (US) 2022-05-04 EP disclosed
CN-108699077-B Heterocyclic compounds as RSV inhibitors 英安塔制药有限公司 2021-03-02 CN disclosed
US-10759816-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-09-01 US disclosed
EP-2951169-B1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-08-28 EP disclosed
US-20190040084-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARM INC (US) 2019-02-07 US disclosed
EP-3402799-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS Enanta Pharmaceuticals, Inc. (US) 2018-11-21 EP disclosed
US-9926333-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2018-03-27 US disclosed
US-20170327514-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2017-11-16 US disclosed
US-9732093-B2 FLAP modulators JANSSEN PHARMACEUTICA NV (BE) 2017-08-15 US disclosed
US-20170226129-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2017-08-10 US disclosed
WO-2017123884-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2017-07-20 WO disclosed
US-20150368270-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-12-24 US disclosed
US-20150252008-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-09-10 US disclosed
US-9073876-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2015-07-07 US disclosed
US-20140221310-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (US) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190040084-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS SIRT1, FURIN, SIRT5 RAB9A 575/4885MAPT 3516/4885SMN1; SMN2 411/4885
US-20170226129-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS SIRT1, FURIN, SIRT5 RAB9A 575/4885MAPT 3516/4885SMN1; SMN2 411/4885
US-20170327514-A1 FLAP MODULATORS FEN1, PGF, TBXA2R RAB9A 2364/4885MAPT 4841/4885SMN1; SMN2 3013/4885
US-20140221310-A1 FLAP MODULATORS FEN1, PGF, PTGIS RAB9A 2184/4885MAPT 4853/4885SMN1; SMN2 3325/4885
US-20150368270-A1 FLAP MODULATORS FEN1, PGF, TBXA2R RAB9A 2364/4885MAPT 4841/4885SMN1; SMN2 3013/4885
US-10759816-B2 Heterocyclic compounds as RSV inhibitors SIRT1, FURIN, SIRT5 RAB9A 575/4885MAPT 3516/4885SMN1; SMN2 411/4885
US-20150252008-A1 FLAP MODULATORS FEN1, PGF, PTGIS RAB9A 2184/4885MAPT 4853/4885SMN1; SMN2 3325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.